BIOPOR Bioporto A/S

Rights issue fully subscribed

Rights issue fully subscribed

April 6, 2020

Announcement no. 8

Rights issue fully subscribed

By company announcement no. 6 of March 16, 2020, BioPorto A/S (“BioPorto”) announced the initiation of a right issue (the “Offering”) with pre-emptive subscription rights for the Company’s existing shareholders allowing for subscription of up to 24,992,054 new shares with a nominal value of DKK 1 each (the “New Shares”).

The subscription period for the New Shares has expired, and BioPorto is pleased to announce that all of the New Shares have been subscribed for. The offering is thus fully subscribed for.

The allocation of subscription orders for remaining shares will be communicated to the individual investors in due course.

The Offering will be completed when payment of subscription amounts have taken place and the New Shares have been registered with the Danish Business Authority, expectedly on April 14, 2020. The expected timetable in BioPorto’s company announcement no. 6 of March 16, 2020 remains unchanged.

Yours sincerely

BioPorto A/S

For further information, please contact:

Peter Mørch Eriksen, CEO

Ole Larsen, CFO

Telephone , e-mail:

About BioPorto

BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

Attachment

EN
06/04/2020

Underlying

BIOPORBioporto A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Tildeling af Warrants

Tildeling af Warrants 28. april 2025Meddelelse nr. 14                                                                          Tildeling af Warrants København, Danmark, den 28. april 2025 (GLOBE NEWSWIRE) – Bestyrelsen for BioPorto A/S ("BioPorto" eller "Selskabet") (CPH:BIOPOR) har i dag implementeret beslutningen fra den ordinære generalforsamling afholdt den 11. april 2025 om at udstede i alt 1.700.000 warrants som en del af vederlaget til medlemmerne af Selskabets bestyrelse. Hver warrant giver indehaveren ret til at tegne én aktie i BioPorto til en udnyttelseskurs på 1.50 kr. pr. a...

April 28, 2025 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Grant of Warrants

Grant of Warrants April 28, 2025Announcement no. 14                                                                          Grant of Warrants Copenhagen, Denmark, April 28, 2025, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has today implemented the resolution of the annual general meeting held on April 11, 2025 to issue a total of 1,700,000 warrants as part of the remuneration to members of the Board of Directors of the Company. Each warrant entitles the holder the right to subscribe for one share in BioPorto at an exercise price...

April 28, 2025 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Ledende medarbejderes transaktioner

Ledende medarbejderes transaktioner 25. april 2025Meddelelse nr. 13                                                                          Ledende medarbejderes transaktioner I forbindelse med gennemførelsen af BioPorto A/S' rettede emission, som beskrevet i selskabsmeddelelse nr. 12, har BioPorto A/S i henhold til artikel 19 i forordning (EU) nr. 596/2014 modtaget indberetning af nedenstående transaktioner vedrørende aktier i BioPorto A/S foretaget af personer med ledelsesansvar i BioPorto A/S og/eller nærtstående til disse. 1 Nærmere oplysninger om personen med ledelsesansvar/persone...

April 25, 2025 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Managers’ transactions

Managers’ transactions April 25, 2025Announcement no. 13                                                                          Managers’ transactions In connection with the completion of BioPorto A/S’ directed issue as described in company announcement no. 12, BioPorto A/S has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons discharging managerial responsibilities in BioPorto A/S and/or persons closely associated with them. 1 Details of the person discharging managerial responsibili...

April 25, 2025 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto A/S rejser 33,5 mio. kr. i ny kapitalrunde - Ændring i antal ...

BioPorto A/S rejser 33,5 mio. kr. i ny kapitalrunde - Ændring i antal aktier og stemmer 25. april 2025Meddelelse nr. 12                                                                          BioPorto A/S rejser 33,5 mio. kr. i ny kapitalrunde - Ændring i antal aktier og stemmer Gennemførelse af kapitalforhøjelse København, Danmark, 25. april 2025, (GLOBE NEWSWIRE) - Bestyrelsen for BioPorto A/S ("BioPorto" eller "Selskabet") (CPH:BIOPOR), en in-vitro diagnostisk virksomhed med fokus på tidlig identifikation og vurdering af akut nyreskade (AKI), besluttede den 15. april 2025 at udstede...

April 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch